At this year’s European Society for Medical Oncology (ESMO) Annual Meeting, pharmaphorum web editor Nicole Raleigh spoke with ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

On Friday 17th October, the European Society for Medical Oncology’s Annual Meeting 2025 kicked off, with the opening press ...

Merck KGaA has become the third pharma company to reach an agreement with the Trump administration to cut the cost of some of ...

Activist investor Shah Capital has called on the board of directors at Novavax to put the company up for sale, citing a ...

Millions of women worldwide live with endometriosis, which causes symptoms like pain and extreme tiredness and, if untreated, ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher ...

Reimbursement authority NICE has said that Apretude (cabotegravir) can now be used as an alternative to daily oral PrEP pills ...

In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh ...

Researchers in the UK have started recruiting patients for a large-scale trial that will test a battery of Parkinson's ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...